Articles

Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas

Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;Epithelial Carcinogenesis Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;Department of Pathology, Fundación Jiménez Díaz, Madrid, Spain
Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;Fundación para la Investigación Biomédica Hospital Universitario Puerta de Hierro, Madrid, Spain
Molecular Diagnostic Unit, CNIO, Madrid, Spain
Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Molecular Diagnostic Unit, CNIO, Madrid, Spain
Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;Epithelial Carcinogenesis Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Translational Research Laboratory, M. D. Anderson Cancer Center Madrid, Spain
Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Experimental Therapeutics Programme, CNIO, Madrid, Spain
Experimental Therapeutics Programme, CNIO, Madrid, Spain
Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain
Department of Pathology, Hospital La Paz, Madrid, Spain
Department of Pathology, Hospital Gregorio Marañón, Madrid, Spain
Department of Pathology, Hospital Ramón y Cajal, Madrid, Spain
Department of Pathology, Instituto i+12, Hospital 12 de Octubre & Medical School Universidad Complutense, Madrid
Department of Dermatology, Instituto i+12, Hospital 12 de Octubre & Medical School Universidad Complutense, Madrid
Translational Research Laboratory, M. D. Anderson Cancer Center Madrid, Spain
Experimental Therapeutics Programme, CNIO, Madrid, Spain
Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;Department of Pathology, Hospital Universitario Marqués de Valdecilla – IFIMAV, Santander, Spain
Vol. 98 No. 1 (2013): January, 2013 https://doi.org/10.3324/haematol.2012.068510